Literature DB >> 19941791

Decrease of hypervirulent Clostridium difficile PCR ribotype 027 in the Netherlands.

M P Hensgens1, A Goorhuis, D W Notermans, B H van Benthem, E J Kuijper.   

Abstract

After the first outbreaks of Clostridium difficile PCR ribotype 027 (North American pulsed-field type 1, restriction endonuclease analysis group BI) in the Netherlands in 2005, a national surveillance programme for C. difficile infection (CDI) was started. Furthermore, national guidelines were developed to rapidly recognise type 027 infections and prevent further spread. The mean incidence of CDI measured in 14 hospitals remained stable throughout the years: an incidence of 18 per 10,000 admissions was seen in 2007 and 2008. Between April 2005 and June 2009 a total of 2,788 samples were available for PCR ribotyping. A decrease was seen in the number and incidence of type 027 after the second half of 2006. In the first half of 2009, the percentage of type 027 isolates among all CDI decreased to 3.0%, whereas type 001 increased to 27.5%. Type 014 was present in 9.3% of the isolates and C. difficile type 078 slightly increased to 9.1%. We conclude that currently there is a significant decrease in type 027-associated CDI in the Netherlands.

Entities:  

Mesh:

Year:  2009        PMID: 19941791     DOI: 10.2807/ese.14.45.19402-en

Source DB:  PubMed          Journal:  Euro Surveill        ISSN: 1025-496X


  28 in total

1.  Binary toxin and its clinical importance in Clostridium difficile infection, Belgium.

Authors:  T Pilate; J Verhaegen; M Van Ranst; V Saegeman
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-07-08       Impact factor: 3.267

2.  Clostridium difficile PCR Ribotype 018, a Successful Epidemic Genotype.

Authors:  Rossella Baldan; Alberto Trovato; Valentina Bianchini; Anna Biancardi; Paola Cichero; Maria Mazzotti; Paola Nizzero; Matteo Moro; Cristina Ossi; Paolo Scarpellini; Daniela Maria Cirillo
Journal:  J Clin Microbiol       Date:  2015-06-03       Impact factor: 5.948

3.  Incidence and economic burden of Clostridioides difficile infection in Ontario: a retrospective population-based study.

Authors:  Jennifer A Pereira; Allison McGeer; Antigona Tomovici; Alex Selmani; Ayman Chit
Journal:  CMAJ Open       Date:  2020-01-30

4.  Clostridium difficile: Changing Epidemiology, Treatment and Infection Prevention Measures.

Authors:  Jane A Cecil
Journal:  Curr Infect Dis Rep       Date:  2012-12       Impact factor: 3.725

Review 5.  The changing epidemiology of Clostridium difficile infections.

Authors:  J Freeman; M P Bauer; S D Baines; J Corver; W N Fawley; B Goorhuis; E J Kuijper; M H Wilcox
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

6.  Trends in incidence of long-term-care facility onset Clostridium difficile infections in 10 US geographic locations during 2011-2015.

Authors:  Alice Y Guh; Yi Mu; James Baggs; Lisa G Winston; Wendy Bamberg; Carol Lyons; Monica M Farley; Lucy E Wilson; Stacy M Holzbauer; Erin C Phipps; Zintars G Beldavs; Marion A Kainer; Maria Karlsson; Dale N Gerding; Ghinwa Dumyati
Journal:  Am J Infect Control       Date:  2018-01-09       Impact factor: 2.918

7.  Expanding the repertoire of conservative site-specific recombination in Clostridioides difficile.

Authors:  Ognjen Sekulovic; Jacob Bourgeois; Aimee Shen; Andrew Camilli
Journal:  Anaerobe       Date:  2019-07-16       Impact factor: 3.331

8.  Treatment of Clostridium difficile infection: recent trial results.

Authors:  Sarah S Lewis; Deverick J Anderson
Journal:  Clin Investig (Lond)       Date:  2013

Review 9.  Acid suppression and the risk of Clostridium difficile infection.

Authors:  Ethan A Mezoff; Mitchell B Cohen
Journal:  J Pediatr       Date:  2013-06-05       Impact factor: 4.406

10.  Antimicrobial susceptibility profiles of human and piglet Clostridium difficile PCR-ribotype 078.

Authors:  Elisabeth C Keessen; Marjolein Pm Hensgens; Patrizia Spigaglia; Fabrizio Barbanti; Ingrid Mjg Sanders; Ed J Kuijper; Len Ja Lipman
Journal:  Antimicrob Resist Infect Control       Date:  2013-04-08       Impact factor: 4.887

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.